Jaguar Health, Inc. filed a current report on Form 8-K on November 20, 2026, disclosing that the company's board of directors approved a 1-for-25 reverse stock split of its common stock, with an effective time of 12:01 a.m. Eastern Time on November 24, 2026.

Key Highlights

  • Split ratio: The board approved a one-for-twenty-five (25) reverse stock split of common stock, par value $0.0001 per share.
  • Effective time: The reverse stock split is set to become effective at 12:01 a.m. Eastern Time on November 24, 2026, under the New Thirteenth Amendment filed with the Delaware Secretary of State.
  • Amended filing correction: An initial amendment filed November 18, 2026, set a November 23 effective date; it was terminated on November 19, 2026, before taking effect, and replaced with a corrected amendment specifying November 24.
  • Stockholder authorization: Stockholders approved a split ratio range of not less than 1-for-2 and not greater than 1-for-150 at a special meeting held on November 6, 2026.
  • No fractional shares: Stockholders otherwise entitled to a fractional share will receive a cash payment in lieu thereof.
  • New CUSIP: The new CUSIP number for the company's common stock following the reverse stock split is 47010C839.
  • Exchange agent: Equiniti Trust Company, LLC is acting as exchange agent for the reverse stock split.

Jaguar Health's 1-for-25 Reverse Split: Filing Details and Amendment Correction

According to the filing, Jaguar Health, Inc. (NASDAQ:JAGX) disclosed that its board of directors exercised authority granted by stockholders at the November 6, 2026, special meeting to approve a one-for-twenty-five reverse stock split of the company's issued and outstanding shares of common stock. The stockholder authorization permitted a ratio anywhere from 1-for-2 to 1-for-150, with the exact ratio left to the board's discretion on or before November 6, 2027.

The filing describes a procedural correction that preceded the final effective date. The company filed an initial certificate of amendment - designated the Thirteenth Amendment - with the Delaware Secretary of State on November 18, 2026, setting the reverse stock split to become effective on November 23, 2026. Before that amendment took effect, the company filed a Certificate of Termination on November 19, 2026, terminating the Thirteenth Amendment. Also on November 19, 2026, the company filed the New Thirteenth Amendment, which carried the same terms but moved the effective time to 12:01 a.m. Eastern Time on November 24, 2026. The filing states that "the Thirteenth Amendment never became effective."

Under the terms described in the filing, every 25 shares of issued and outstanding common stock immediately prior to the effective time will automatically be reclassified into one share, with no change to the par value per share. The reverse stock split will reduce shares issuable under outstanding stock options and warrants proportionately and cause a proportionate increase in their conversion and exercise prices. Shares reserved under the company's equity compensation plans will also be reduced proportionately. The filing states the total number of authorized shares of common stock or preferred stock will not change. Trading on The Nasdaq Capital Market on a split-adjusted basis is stated to commence on November 24, 2026.

What Was Disclosed

Jaguar Health disclosed the approval and mechanics of a 1-for-25 reverse stock split effective November 24, 2026, including a correction of an initially filed amendment that had set a November 23 effective date, the new CUSIP number, and the role of Equiniti Trust Company, LLC as exchange agent.